北京——Zephyr AI，一家专注于开发快速且可解释的人工智能技术以推动精准医疗的初创公司，近日宣布成功获得1.11亿美元的A轮融资。这轮融资由知名投资机构Revolution Growth领投，医药巨头礼来公司、社会企业家Jeff Skoll以及EPIQ Capital Group等重量级投资者参与跟投。这一消息来源于权威的BusinessWire。
Zephyr AI的创新技术旨在为医疗行业提供更高效、更精准的诊断和治疗方案，通过其独特的人工智能算法，有望改变医疗领域的决策制定过程。此轮融资的成功，不仅彰显了市场对Zephyr AI技术潜力的认可，也为公司进一步研发和扩大业务规模提供了强大的资金支持。
礼来公司的参与，预示着医药行业对AI在医疗领域应用的浓厚兴趣，可能预示着未来医药研发与人工智能的深度结合。而Jeff Skoll的加入，也体现了社会影响力投资对于科技改善医疗健康领域的期待。
Zephyr AI的创始人兼首席执行官表示：“这笔资金将用于加速我们的研发进程，提高AI算法的性能，并扩大我们的团队，以便为全球更多的医疗机构提供服务。我们致力于让精准医疗变得更加普及和可及，这次融资是我们实现这一愿景的重要里程碑。”
此次A轮融资的成功，无疑为Zephyr AI在精准医疗AI领域的领先地位奠定了坚实基础，同时也为医疗行业带来了更多创新与可能性。
英语如下：
**News Title:** “Zephyr AI Secures $110M in Series A Funding, Pioneering a New Era in Precision Medicine AI”
**Keywords:** Zephyr AI, precision medicine, Series A funding
**News Content:**
**Beijing** — Zephyr AI, a startup focused on developing fast and explainable artificial intelligence (AI) technologies for precision medicine, has announced the successful completion of a $110 million Series A funding round. The round was led by prominent investment firm Revolution Growth, with significant participation from pharmaceutical giant Eli Lilly, social entrepreneur Jeff Skoll, and EPIQ Capital Group, among others, as reported by BusinessWire.
Zephyr AI’s innovative technology aims to provide the healthcare industry with more efficient and accurate diagnostic and treatment options through its unique AI algorithms, potentially transforming decision-making processes in healthcare. This funding round not only underscores the market’s recognition of Zephyr AI’s technological potential but also furnishes the company with substantial financial backing to further its research and expand its operations.
Eli Lilly’s involvement signals the pharmaceutical industry’s strong interest in AI applications in healthcare, potentially foreshadowing a deeper integration of AI in drug development. Jeff Skoll’s participation highlights the expectation for impact investing in technology-driven improvements to healthcare.
The founder and CEO of Zephyr AI stated, “These funds will accelerate our R&D, enhance the performance of our AI algorithms, and expand our team to serve more healthcare institutions globally. We are dedicated to making precision medicine more accessible and widespread, and this financing is a significant milestone in realizing that vision.”
This successful Series A funding firmly establishes Zephyr AI’s leadership position in the precision medicine AI sector and opens up new horizons of innovation and potential for the healthcare industry.
【来源】https://www.businesswire.com/news/home/20240312475536/en/Zephyr-AI-Raises-111-Million-in-Series-A-Financing
Views: 1